Amir Gal-Or, MBA – Managing Partner, Infinity Equity
Amir Gal-Or is the managing partner of Infinity Equity, which manages more than US$600M and 45 late-stage portfolio companies. Mr. Gal-Or is an international private equity/venture capitalist with a stellar track record in identifying, leading and building growth companies and securing significant returns for fellow investors.
In 2004, together with his partners, Mr. Gal-Or championed the establishment of the first limited partnership on shore venture capital fund in China, the Infinity-CSVC Fund, an alliance between Infinity/IDB and Suzhou Investment arm, CSVC.
Mr. Gal-Or earned an MBA from Tel Aviv University and is a graduate of Harvard University's program in venture capital and private equity investments. He is a former pilot in the Israeli Air Force and its acrobatic team. Mr. Gal-Or is a member of the World Economic Forum.
William Hu, MBA - Principal, Qiming Venture Partners
William Hu joined Qiming in 2006, focusing on the investment in healthcare sector. He has over 9 years of investing, strategy consulting, and operating experience in the healthcare industry. Prior to joining Qiming Ventures, he was the director with CITIC Future Investment, strategy/healthcare consultant with IBM BCS, and product manager with Colorcon. He received his B.S. in Medicine from Shanghai Medical University (now Medical School of Fudan University) and MBA from SIMBA, ENPC (Paris) Shanghai campus
Kewen Jin, PhD - CEO, Charles River Laboratories (China)
Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007.
Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in drug discovery, R&D outsourcing, and life science consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the
He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the
He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (
Karen Liu, PhD – Vice President, China Renaissance Capital
Dr. Karen Liu has over 10 years of work experience in China; Her past experiences include two years of management consulting at McKinsey & Company and a successful 4-year entrepreneurship helping to build up one of the leading Internet company in China and eventually sold the company to Yahoo; Dr. Liu had also been an active angel investor in the biotechnology sector. She is a founder and angel investor for Shenogen Pharma Group, a new drug development venture with a promising pipeline of anti-cancer drugs. Dr. Liu currently works full time as a VC at CRCI Capital, a premier
Yuwen Liu, MBA – General Manager, BioBay
Liu Yuwen graduated from China Pharmaceutical University with an Ms in Pharmaceutics and MBA at Fudan University, China and Norwegian Management School, and is a licensed pharmacist.
She started her career with Capsugel® , a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to be QA manager in April 1998. In May 2000, following strategic expansion of Capsugel China, she transferred to New Business Development department managing new product market opportunity exploration in great China region.
In May 2003, she moved to Shanghai as General Manager to set up the representative office for Perrigo Company (the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand market) and is taking charge of all related market development activities including JV’s in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc.
In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development in China. August, 2007, she became the general manager of BioBay, vice president of Suzhou Ventures Group, assistance director of Suzhou Industrial Park Science & Technology Bureau.
Don Qiu, PhD, MBA – General Manager, China, ChinaBio® LLC
Dr. Don Qiu leads ChinaBio’s
Greg B. Scott - President and Founder, ChinaBio® Accelerator and Founding Principal, ChinaBio® Consulting
Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded ChinaBio® Accelerator to help fund and mentor early stage life science companies in China. He is also the Founding Principal of ChinaBio® Consulting which assists U.S. and China life science companies and investors leverage the opportunities available in China. He also serves as the chairman and acting CEO for ChinaBio® Therapeutics, created to in-license and develop novel drugs in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 22 biotechnology and medical device companies since 2005, and executive editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was the co-founder of a 200-person consulting firm. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
Yi Shi, PhD - Managing Director, Lilly Asian Ventures
Dr. Yi Shi joined Lilly Asian Ventures in 2007 as a Managing Director based in Shanghai, China. Prior to the current assignment, he worked in various roles with increasing responsibility over six years at Eli Lilly and Company. His experience includes leading the development of a comprehensive investment strategy for China as well as negotiating multiple biotechnology and pre-clinical deals world-wide. Dr. Shi was also instrumental in the founding of InnoCentive, Inc., a Lilly Ventures portfolio company, where he managed scientific operations as well as its expansion into China.
Before joining Lilly, Dr. Shi was the Chief Sales and Marketing Officer of NetBig.com, an internet start-up, where he successfully grew the company to become the number one education and technology portal in China. He began his career as a management consultant with Ernst & Young in the Life Science Practice Group and specialized in sales and marketing strategy. Dr. Shi received a Ph.D. in Biochemistry and a Master of Business Administration degree, both from Duke University. He also earned a Bachelor of Science in Biology from the University of Science and Technology of China.
Zoe Wang, PhD, JD – Partner, Perkins Coie LLP
Dr. Zhaohui (Zoe) Wang focuses her practice on patent infringement and validity opinions, patent prosecution, freedom-to-operate analyses, patentability analyses, technology transfers and licensing. Her work involves technologies in the fields of life sciences, nanotechnologies, data processing, and devices.
She also has experience advising clients in public offerings and private placements of equity and debt securities, mergers and acquisitions, counseling companies on general corporate matters, and advising clients with respect to the Securities Act of 1933, the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002.
She received her J.D. from Columbia University School of Law in 1999 and her Ph.D. in cell biology and biophysics from Duke University in 1996.
David Xu, PhD - Managing Partner, Mingly China Growth Fund
David Xu is the Managing Partner of Mingly China Growth Fund. David has over 10 years of investment banking experience in China. Previously, David worked at EBICC, Create Capital, China Fortune Securities and Goldman Sachs. He also worked as a research fellow at Columbia Medical Center for 7 years. David received his BS degree from University of Science & Technology of China, Ph.D. in Microbiology from Columbia University, and MBA from MIT Sloan School of Management.
Michael Xu, MD, PhD - CEO, PegBio Co., Ltd
Dr. Xu, whose expertise encompasses medicine, protein structure, pharmaceutical management, he completed his M.D. degree from Hunan Medical University and Ph.D. degree in Physiology and Biophysics from Columbia University at New York. Prior to found the Company, he was a GM of a joint venture pharmaceutical company in China for several years. Dr. Xu had published many scientific papers including in Science.
Zhi Yang, PhD – Co-founder and Managing Partner, BioVeda China
Dr. Zhi Yang is co-founder and Managing Partner of BioVeda China. He has over two decades of experience in biotechnology, having held senior scientific and management positions in a variety of biotech and pharmaceutical companies, including Sinogen, Incyte Pharmaceuticals, Prolinx, Sandoz Pharmaceuticals, and Systemix. During his industry years, he was interim CEO, VP Business Development, VP of R&D, Director of Molecular Biology, Group Leader and Senior/Principal Scientist. As an entrepreneur, he co-founded BioChain Institute, Genex Biosciences and Crimson Pharmaceuticals. He is also the principal inventor of more than 10 U.S. and international patents. Prior to joining industry, Zhi was a senior associate fellow and faculty member at Rockefeller University. He holds a M.A., Ph.D. in Biochemistry and Molecular Biology from Harvard University, where his thesis advisors were Dr. Walter Gilbert, a Nobel laureate, and Dr. Jack Strominger, a world-renowned immunologist. Zhi was among the first group of CUSBEA students from China to study in the U.S. He obtained his B.S. in Virology from Wuhan University.
Qimin Zhan, MD – Chief Scientist, State 863 Program
Dr. Qimin Zhan is the Vice President of Chinese Academy of Medical Sciences and the Director of the National Laboratory of Molecular Oncology. He received his medical degree in Suzhou University Medical College and completed his graduate study in the Peking Union Medical College. Dr. Zhan had postdoctoral experience in the University of California San Francisco, University of Texas Southwestern Medical Center at Dallas and the National Cancer Institute, NIH, and was a tenured faculty in the University of Pittsburgh School of Medicine. He is currently a Professor in Peking Union Medical College and a Senior Investigator in Chinese Academy of Medical Sciences Cancer Institute, Beijing, China. Dr. Zhan is also the Chairman of the National Advisory Board for 863 High-Tech plan in the field of biomedical sciences and the Chief Scientist of the 973 National Fundamental Program (cancer research field). Dr. Zhan’s research interest is focused on the molecular pathways involved in the control of cell cycle checkpoint and apoptosis after DNA damage. He is also interested in signaling pathways involved in regulation of the maintenance of genomic stability and tumor metastasis. His research has successfully attracted multiple grants from different funding agencies. Dr. Zhan’s has totally published more than 80 peer-reviewed SCI papers. Most of his publications are in prestigious journals, including Cell, Journal of Molecular and Cellular Biology, Science, Cancer Research, Oncogene, Journal of Biological Chemistry and the Proceedings of the National Academy of Sciences. Many of his papers have been highly cited in the biomedical field. Currently, his publications have been cited more than 8000 times (SCI database). Dr. Zhan is a member in the editorial board for Journal of Cancer Biology and Therapy and the journal of Carcinogenesis, and also a frequent reviewer for Cancer Research, Oncogene, Journal of Molecular Pharmacology, Experimental Cell Research, Radiation Research, and Mutation Research.
Dongchi Zhang, MD, Director, Science and Technology Bureau，Suzhou Industrial Park Administrative Committee
Dongchi Zhang, graduated from East China Normal University, biology Dept., Fujian Normal University, Master in biochemistry. He is the director of Science and Technology Bureau, Suzhou Industrial Park Administrative Committee. Before he joined the Science and Technology Bureau, Mr. Zhang worked as a Deputy Director of Investment Bureau, Suzhou Industrial Park. He has been successfully in charge of Economic and Trade Bureau, Suzhou Industrial Park Committee. He was the Deputy Head of Fuzhou Termite Control Institute. He also made significant contributions to Suzhou Biochemical Pharm Ltd. as an Engineer.
Peter Zhang, PhD - Chairman & CEO, Suzhou GenePharma Co., Ltd.
Dr. Peter Zhang graduated from Beijing University in 1988 and got his Ph.D. degree in Medicinal Chemistry. After that he worked for State Pharmaceutical Administration in Beijing for two years. In 1991 he joined Prof. C. B. Reese’s group in King’s College London to study nucleic acid chemistry. For more than five years in Prof. Reese’s lab, he was involved in developing new RNA chemistry, modification of nucleosides for antisense study, and methodology study in solution and solid phase DNA/RNA synthesis. In 1996, Dr. Zhang joined Cruachem Ltd. in Scotland, and started to work as Senior Nucleic Acid Chemist to develop new products, undertaking contract synthesis work. In 1998 he was promoted to the position of Specialty Chemicals Group Leader, taking the responsibility of directing new products development and specialty chemicals production. At the same time he was involved in technical support work, and in charge of sales work of South East Asia area. In 2003, he and other co-founders founded Shanghai GenePharma Co., Ltd. in China. The company is dedicated to develop RNA interference related new products and supply services to the RNAi research community.
Wei Zhou, PhD, JD - Partner, WSGR
Dr. Wei Zhou is a partner at Wilson Sonsini Goodrich & Rosati, P.C., a leading law firm focusing on technology and growth company legal issues, where he focuses on corporate and intellectual property issues facing life sciences companies in the United States and China.Dr. Zhou obtained his J.D. from Stanford Law School, his Ph.D. from Virginia Tech. He is also a graduate of the General Management Program at Harvard Business School.